Zucero is pleased to announce approval has been granted to expand its current Phase 1b study to include patients with a particular form of bowel cancer known as microsatellite stable metastatic colorectal cancer (MSS mCRC).
The Board of Zucero Therapeutics Limited (Zucero) is pleased to confirm that it has completed payment of the $5,999,000 deferred consideration payable to ASX listed biotech TBG Diagnostics Ltd (ASX Code:TDL) (TBG) following the purchase by Zucero of the PG500 IP Assets in August 2016.
Early results from a phase I trial in a small group of patients with advanced cancer using two drugs (nivolumab and pixatimod) that stimulate the immune system report that patients with bowel cancer may benefit from the combination.
In this research article published in the British Journal of Cancer in 2018, the authors conclude that PG545 (pixatimod) demonstrated a tolerable safety profile, proportional PK, evidence of immune cell stimulation and disease control in some subjects. Taken together, these data support the proposed mechanism of action, which represents a promising approach for use in combination with existing therapies .
In this research article published in the Journal for Immunotherapy of Cancer on 14 June 2018, the authors discuss how Pixatimod modulates innate immune cells but also enhances T cell infiltration in combination with anti-PD-1 therapy.